Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.


Live to eat and eat to live longer.

Adler A. and Saksena R., (2023), Nat Food

Timing of SGLT2i initiation after acute myocardial infarction.

von Lewinski D. et al, (2023), Cardiovasc Diabetol, 22

Teplizumab approval for type 1 diabetes in the USA.

Beran D. et al, (2023), Lancet Diabetes Endocrinol, 11, 78 - 80


A brief history of the UK Prospective Diabetes Study

Holman RR., (2022), BRITISH JOURNAL OF DIABETES, 22, S32 - S35

Empagliflozin in acute Myocardial Infarction: the EMMY trial.

von Lewinski D. et al, (2022), Eur Heart J


The STEP 1 trial for weight loss: a step change in treating obesity?

Adler AI., (2021), Nature Medicine, 27, 589 - 590

Adjusting for Nonadherence or Stopping Treatments in Randomized Clinical Trials.

Adler AI. and Latimer NR., (2021), JAMA, 325, 2110 - 2111

Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.

Blood Pressure Lowering Treatment Trialists' Collaboration None., (2014), Lancet, 384, 591 - 598


Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.

Donnelly LA. et al, (2020), Diabetes Care, 43, 2493 - 2499